title: Immunological monitoring of the tumor immunoenvironment for clinical trials.
abstract: Monitoring of immunotherapeutic clinical trials has undergone a considerable change in the last decade resulting in a general agreement that immune monitoring should guide the development of cancer vaccines. The emphasis on immune cell functions and quantitation of antigen-specific T cells have been playing a major role in the attempts to establish meaningful correlations between therapy-induced alterations in immune responses and clinical endpoints. However, one significant unresolved issue in modern immunotherapy is that when a tumor-specific cellular immune response is observed following the course of immunotherapy, it does not always lead to clinically proven cancer regression. This disappointing lack of a correlation between the tumor-specific cytotoxic immune responses and the clinical efficacy of immunotherapy may be explained, among other reasons, by the notion that the analysis of any single immunological parameter is not sufficient to provide clinically feasible information about the complex interactions between different cell subsets in the peripheral blood and immune, tumor, and stromal cells in the tumor milieu. By contrast, a systemic approach is required for improving the quality of a serial monitoring to ensure that it adequately and reliably measures potential changes induced in patients by administered vaccines or immunomodulators. Comprehensive evaluation of the balance between the immunostimulatory and immunosuppressive compartments of the immune system could be critical for a better understanding of how a given immunotherapy works or does not work in a particular clinical trial. New approaches to characterize tumor-infiltrating leukocytes, their phenotypic, biochemical, and genetic characteristics within the tumor microenvironment need to be developed and validated and should complement current monitoring techniques. These immune-monitoring assays for the local tumor immunoenvironment should be developed, validated, and standardized for reliability and consistency in order to establish the overall performance standards.
authors.affiliation: Laboratory of Cell-Mediated Immunity, SAIC-Frederick, Inc., P.O. Box B, Frederick, MD, 21702, USA. malyguinea@mail.nih.gov.
authors.forename: Anatoli M
authors.initials: AM
authors.lastname: Malyguine
authors.affiliation: Laboratory of Cell-Mediated Immunity, SAIC-Frederick, Inc., P.O. Box B, Frederick, MD, 21702, USA.
authors.forename: Susan L
authors.initials: SL
authors.lastname: Strobl
authors.affiliation: Department of Pathology, Division of Clinical Immunopathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
authors.forename: Michael R
authors.initials: MR
authors.lastname: Shurin
mesh_terms: D019496:Cancer Vaccines; D002986:Clinical Trials as Topic; D006801:Humans; D007167:Immunotherapy; D015166:Monitoring, Immunologic / Q000639:trends; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology*; D016896:Treatment Outcome; D059016:Tumor Microenvironment
chemical_list: D019496:Cancer Vaccines
references.citation: Cancer. 2008 Sep 15;113(6):1387-95
references.pmid: 18671239
references.citation: Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):3967-72
references.pmid: 17360461
references.citation: N Engl J Med. 2011 Jun 2;364(22):2119-27
references.pmid: 21631324
references.citation: Neuro Oncol. 2010 Jul;12(7):631-44
references.pmid: 20179016
references.citation: Immunol Rev. 2011 Jan;239(1):27-44
references.pmid: 21198663
references.citation: J Pathol. 2002 Mar;196(3):254-65
references.pmid: 11857487
references.citation: J Clin Oncol. 2011 May 20;29(15):1949-55
references.pmid: 21483002
references.citation: Trends Immunol. 2011 Jan;32(1):19-25
references.pmid: 21067974
references.citation: J Innate Immun. 2011;3(4):344-54
references.pmid: 21576922
references.citation: Immunol Lett. 2001 Aug 1;78(1):35-9
references.pmid: 11470149
references.citation: J Clin Oncol. 2009 Jan 10;27(2):186-92
references.pmid: 19064967
references.citation: Gastroenterology. 2009 Oct;137(4):1270-9
references.pmid: 19577568
references.citation: Prostate. 2010 Mar 1;70(4):443-55
references.pmid: 19902470
references.citation: Nat Med. 2004 Sep;10(9):909-15
references.pmid: 15340416
references.citation: Semin Cancer Biol. 2011 Apr;21(2):131-8
references.pmid: 21145968
references.citation: Immunol Rev. 2011 May;241(1):104-18
references.pmid: 21488893
references.citation: Cancer Res. 2004 Aug 15;64(16):5535-8
references.pmid: 15313886
references.citation: Surgery. 2009 Mar;145(3):286-93
references.pmid: 19231581
references.citation: Immunol Res. 2011 Aug;50(2-3):276-85
references.pmid: 21717082
references.citation: Curr Cancer Drug Targets. 2011 Jul;11(6):734-51
references.pmid: 21599634
references.citation: Cancer Invest. 2008 Dec;26(10):1024-31
references.pmid: 19093260
references.citation: Blood. 2011 Aug 25;118(8):2254-65
references.pmid: 21734236
references.citation: Cancer Res. 1996 Oct 15;56(20):4625-9
references.pmid: 8840975
references.citation: Cancer Immun. 2007 Feb 21;7:4
references.pmid: 17311363
references.citation: Cancer Immunol Immunother. 2010 May;59(5):663-74
references.pmid: 19890632
references.citation: Cancer Immunol Immunother. 2009 Jan;58(1):49-59
references.pmid: 18446337
references.citation: Nat Rev Immunol. 2003 May;3(5):361-70
references.pmid: 12766758
references.citation: J Clin Oncol. 2007 Jun 20;25(18):2546-53
references.pmid: 17577033
references.citation: Cancer Res. 2007 Jan 1;67(1):354-61
references.pmid: 17210718
references.citation: Int J Oncol. 2006 Jun;28(6):1345-52
references.pmid: 16685435
references.citation: Med Oncol. 2012 Sep;29(3):1817-26
references.pmid: 21678026
references.citation: Cancer Res. 2010 Jan 1;70(1):68-77
references.pmid: 20028852
references.citation: J Immunother. 2000 May-Jun;23(3):289-95
references.pmid: 10838657
references.citation: J Transl Med. 2007 Nov 29;5:62
references.pmid: 18047662
references.citation: J Hepatol. 2011 Mar;54(3):497-505
references.pmid: 21112656
references.citation: J Allergy Clin Immunol. 2010 Feb;125(2 Suppl 2):S272-83
references.pmid: 20061007
references.citation: Adv Exp Med Biol. 2007;601:273-84
references.pmid: 17713015
references.citation: Breast Cancer Res Treat. 2011 Nov;130(2):645-55
references.pmid: 21717105
references.citation: Exp Biol Med (Maywood). 2011 May 1;236(5):567-79
references.pmid: 21486861
references.citation: J Invest Dermatol. 1993 Mar;100(3):335S-341S
references.pmid: 8440919
references.citation: J Immunol Methods. 2000 Jun 23;240(1-2):143-55
references.pmid: 10854609
references.citation: J Clin Oncol. 2011 Jan 20;29(3):330-6
references.pmid: 21149657
references.citation: Cancer Immunol Immunother. 2009 Mar;58(3):449-59
references.pmid: 18791714
references.citation: Cancer Metastasis Rev. 2006 Sep;25(3):333-56
references.pmid: 17029028
references.citation: J Transl Med. 2010 Sep 27;8:89
references.pmid: 20875102
references.citation: J Transl Med. 2004 Mar 29;2(1):9
references.pmid: 15050026
references.citation: J Clin Oncol. 2009 Dec 10;27(35):5944-51
references.pmid: 19858404
references.citation: Clin Cancer Res. 2011 May 15;17(10):3064-76
references.pmid: 21558394
references.citation: J Transl Med. 2003 Dec 29;1(1):14
references.pmid: 14697097
references.citation: J Immunother. 2006 May-Jun;29(3):328-35
references.pmid: 16699376
references.citation: J Immunother. 2005 Jul-Aug;28(4):396-402
references.pmid: 16000959
references.citation: Oncogene. 2010 Feb 25;29(8):1093-102
references.pmid: 19946335
references.citation: J Immunother. 2009 Feb-Mar;32(2):186-94
references.pmid: 19238018
references.citation: J Immunol. 2005 Nov 1;175(9):6169-76
references.pmid: 16237114
references.citation: Cancer Res. 2008 Jul 1;68(13):5439-49
references.pmid: 18593947
references.citation: Cancer Immunol Immunother. 2008 Dec;57(12):1795-805
references.pmid: 18414854
references.citation: Cancer J. 2010 Jul-Aug;16(4):348-53
references.pmid: 20693846
references.citation: Int J Cancer. 2011 Aug 1;129(3):636-47
references.pmid: 20857491
references.citation: Cancer Immun. 2008 Dec 04;8:16
references.pmid: 19053167
references.citation: Cancer Res. 2000 Oct 15;60(20):5857-61
references.pmid: 11059783
references.citation: Expert Opin Biol Ther. 2010 Nov;10(11):1539-53
references.pmid: 20955111
references.citation: Cancer Res. 2011 Sep 1;71(17):5670-7
references.pmid: 21846824
references.citation: Cancer Immunol Immunother. 2011 Aug;60(8):1153-60
references.pmid: 21553145